{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T19:24:26Z","timestamp":1777922666888,"version":"3.51.4"},"reference-count":116,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2014,3,20]],"date-time":"2014-03-20T00:00:00Z","timestamp":1395273600000},"content-version":"vor","delay-in-days":19,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Evid.\u2010Based Child Health"],"published-print":{"date-parts":[[2014,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>The morbidity and treatment costs associated with skin and soft tissue infections (SSTIs) are high. Linezolid and vancomycin are antibiotics that are commonly used in treating skin and soft\u2010tissue infections, specifically those infections due to methicillin\u2010resistant <jats:italic>Staphylococcus aureus (<\/jats:italic>MRSA).<\/jats:p><\/jats:sec><jats:sec><jats:title>Objectives<\/jats:title><jats:p>To compare the effects and safety of linezolid and vancomycin for treating people with SSTIs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Search methods<\/jats:title><jats:p>In May 2013 we conducted searches of the following databases: Cochrane Wounds Group Specialised Register; The Cochrane Central Register of Controlled Trials (CENTRAL) (<jats:italic>The Cochrane Library<\/jats:italic>); Ovid MEDLINE; Ovid MEDLINE (In\u2010Process &amp; Other Non\u2010Indexed Citations); Ovid EMBASE; and EBSCO CINAHL. We also contacted manufacturers for details of unpublished and ongoing trials. We scrutinised citations within all obtained trials and major review articles to identify any additional trials.<\/jats:p><\/jats:sec><jats:sec><jats:title>Selection criteria<\/jats:title><jats:p>We included all randomised controlled trials (RCTs) comparing linezolid with vancomycin in the treatment of SSTIs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Data collection and analysis<\/jats:title><jats:p>Two review authors independently selected trials, assessed risk of bias and extracted data. The primary outcomes were clinical cure, microbiological cure, and SSTI\u2010related and treatment\u2010related mortality. We performed subgroup analyses according to age, and whether the infection was due to MRSA.<\/jats:p><\/jats:sec><jats:sec><jats:title>Main results<\/jats:title><jats:p>We included nine RCTs (3144 participants). Linezolid was associated with a significantly better clinical (RR 1.09, 95% CI 1.03 to 1.16) and microbiological cure rate in adults (RR 1.08, 95% CI 1.01 to 1.16). For those infections due to MRSA, linezolid was significantly more effective than vancomycin in clinical (RR 1.09, 95% CI 1.03 to 1.17) and microbiological cure rates (RR 1.17, 95% CI 1.04 to 1.32). No RCT reported SSTI\u2010related and treatment\u2010related mortality. There was no significant difference in all\u2010cause mortality between linezolid and vancomycin (RR 1.44, 95% CI 0.75 to 2.80). There were fewer incidents of red man syndrome (RR 0.04, 95% CI 0.01 to 0.29), pruritus (RR 0.36, 95% CI 0.17 to 0.75) and rash (RR 0.27, 95% CI 0.12 to 0.58) in the linezolid group compared with vancomycin, however, more people reported thrombocytopenia (RR 13.06, 95% CI 1.72 to 99.22), and nausea (RR 2.45, 95% CI 1.52 to 3.94) when treated with linezolid. It seems, from the available data, that length of stay in hospital was shorter for those in the linezolid group than the vancomycin group. The daily cost of outpatient therapy was less with oral linezolid than with intravenous vancomycin. Although inpatient treatment with linezolid cost more than inpatient treatment with vancomycin per day, the median length of hospital stay was three days shorter with linezolid. Thus, total hospital charges per patient were less with linezolid treatment than with vancomycin treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Authors' conclusions<\/jats:title><jats:p>Linezolid seems to be more effective than vancomycin for treating people with SSTIs, including SSTIs caused by MRSA. The available evidence is at high risk of bias and is based on studies that were supported by the pharmaceutical company that makes linezolid. Further well\u2010designed, independently\u2010funded, RCTs are needed to confirm the available evidence.<\/jats:p><\/jats:sec><jats:sec><jats:title>Plain Language Summary<\/jats:title><jats:p><jats:bold>Antibiotic drugs for treating skin and soft tissue infections<\/jats:bold><\/jats:p><jats:p>Skin and soft tissue infections such as impetigo, abscesses, ulcers, and surgical site infections are common infections of the skin. For serious skin and soft tissue infections involving the deeper tissues, the death rate and treatment costs are high. Linezolid and vancomycin are antibiotics that are effective in treating skin and soft tissue infections, particularly infections caused by bacteria that have developed resistance to some antibiotics. This review identified nine RCTs, with a total of 3144 participants, and compared treatment with linezolid against treatment with vancomycin for skin and soft tissue infections. Linezolid was found to be more effective than vancomycin for treating these infections. There were fewer skin complications in the group that were treated with linezolid. There were no differences between the two groups in the number of reported deaths, and those treated with linezolid had shorter lengths of hospital stay than those treated with vancomycin. The daily cost of outpatient therapy was less with oral linezolid than with intravenous vancomycin, although for inpatient treatment, linezolid was more expensive than vancomycin. Well\u2010designed trials will be required in future to confirm these results, as the trials from which these conclusions were drawn were of poor methodological quality, at high risk of bias, and were funded by the pharmaceutical company that makes linezolid.<\/jats:p><\/jats:sec>","DOI":"10.1002\/ebch.1961","type":"journal-article","created":{"date-parts":[[2014,3,20]],"date-time":"2014-03-20T13:46:34Z","timestamp":1395323194000},"page":"103-166","source":"Crossref","is-referenced-by-count":3,"title":["Linezolid versus vancomycin for skin and soft tissue infections"],"prefix":"10.1002","volume":"9","author":[{"given":"Jirong","family":"Yue","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bi Rong","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaomei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taixiang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guan J","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,3,20]]},"reference":[{"key":"e_1_2_15_2_1","unstructured":"References to studies included in this review"},{"key":"e_1_2_15_3_1","unstructured":"Itani 2010 {published data only}"},{"key":"e_1_2_15_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjsurg.2009.08.045"},{"key":"e_1_2_15_5_1","unstructured":"Jaksic 2006 {published data only}"},{"key":"e_1_2_15_6_1","doi-asserted-by":"publisher","DOI":"10.1086\/500139"},{"key":"e_1_2_15_7_1","unstructured":"Kohno 2007 {published data only}"},{"key":"e_1_2_15_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkm369"},{"key":"e_1_2_15_9_1","unstructured":"Lin 2008 {published data only}"},{"issue":"1","key":"e_1_2_15_10_1","first-page":"10","article-title":"A randomized, double\u2010blinded, controlled, multicenter clinical trial of linezolid versus vancomycin in the treatment of gram positive bacterial infection","volume":"9","author":"Lin DF","year":"2009","journal-title":"Chinese Journal of Infection and Chemotherapy"},{"key":"e_1_2_15_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2008.04.004"},{"key":"e_1_2_15_12_1","unstructured":"Sharpe 2005 {published data only}"},{"key":"e_1_2_15_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjsurg.2005.01.011"},{"key":"e_1_2_15_14_1","unstructured":"Stevens 2002 {published data only}"},{"key":"e_1_2_15_15_1","doi-asserted-by":"publisher","DOI":"10.1089\/109629603764655290"},{"key":"e_1_2_15_16_1","doi-asserted-by":"publisher","DOI":"10.1592\/phco.21.3.263.34198"},{"key":"e_1_2_15_17_1","doi-asserted-by":"publisher","DOI":"10.1086\/340353"},{"key":"e_1_2_15_18_1","unstructured":"Weigelt 2005 {published data only}"},{"key":"e_1_2_15_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2005.09.003"},{"key":"e_1_2_15_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(07)80085-3"},{"key":"e_1_2_15_21_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1G728"},{"key":"e_1_2_15_22_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.6.2260-2266.2005"},{"key":"e_1_2_15_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjsurg.2004.08.045"},{"key":"e_1_2_15_24_1","unstructured":"Wilcox 2009 {published data only}"},{"key":"e_1_2_15_25_1","doi-asserted-by":"publisher","DOI":"10.1086\/595686"},{"key":"e_1_2_15_26_1","unstructured":"Yogev 2003 {published data only}"},{"key":"e_1_2_15_27_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.inf.0000086955.93702.c7"},{"key":"e_1_2_15_28_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.inf.0000087020.75886.93"},{"key":"e_1_2_15_29_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.inf.0000088671.35064.7c"},{"key":"e_1_2_15_30_1","unstructured":"References to studies excluded from this review"},{"key":"e_1_2_15_31_1","unstructured":"Bounthavong 2009 {published data only}"},{"key":"e_1_2_15_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2008.01958.x"},{"key":"e_1_2_15_33_1","unstructured":"Hau 2002 {published data only}"},{"key":"e_1_2_15_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-002-0753-x"},{"key":"e_1_2_15_35_1","unstructured":"Joseph 2007 {published data only}"},{"issue":"1","key":"e_1_2_15_36_1","first-page":"26","article-title":"Commentary on Linezolid eradicates MRSA better than vancomycin from surgical\u2010site infections","volume":"19","author":"Joseph WS","year":"2007","journal-title":"Foot and Ankle Quarterly\u2010\u2010The Seminar Journal"},{"key":"e_1_2_15_37_1","unstructured":"Kalil 2006 {published data only}"},{"key":"e_1_2_15_38_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.50.5.1910-1911.2006"},{"key":"e_1_2_15_39_1","unstructured":"Lipsky 2011 {published data only}"},{"key":"e_1_2_15_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2010.10.003"},{"key":"e_1_2_15_41_1","unstructured":"McKinnon 2007 {published data only}"},{"issue":"1","key":"e_1_2_15_42_1","first-page":"23","article-title":"Health economics. The economic effect of oral linezolid versus intravenous vancomycin in the outpatient setting: the payer perspective","volume":"20","author":"McKinnon PS","year":"2007","journal-title":"Managed Care Interface"},{"key":"e_1_2_15_43_1","unstructured":"Patanwala 2007 {published data only}"},{"key":"e_1_2_15_44_1","doi-asserted-by":"publisher","DOI":"10.1185\/030079906X162700"},{"key":"e_1_2_15_45_1","unstructured":"Schurmann 2009 {published data only}"},{"key":"e_1_2_15_46_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10198-008-0104-7"},{"key":"e_1_2_15_47_1","unstructured":"Additional references"},{"key":"e_1_2_15_48_1","unstructured":"Beibei 2010"},{"key":"e_1_2_15_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2009.09.013"},{"key":"e_1_2_15_50_1","unstructured":"Bounthavong 2010"},{"key":"e_1_2_15_51_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007990903454912"},{"key":"e_1_2_15_52_1","unstructured":"Bouza 2004"},{"issue":"8","key":"e_1_2_15_53_1","first-page":"1161","article-title":"Bloodstream infections: a trial of the impact of different methods of reporting positive blood culture results","volume":"39","author":"Bouza E","year":"2004","journal-title":"Journal of Infectious Diseases"},{"key":"e_1_2_15_54_1","unstructured":"Deeks 2011"},{"key":"e_1_2_15_55_1","unstructured":"DeeksJJ HigginsJPT AltmanDG on behalf of theCochrane Statistical Methods Group and the CochraneBias Methods Group (Editors). Chapter 9: Analysing data and undertaking meta\u2010analyses.In: Higgins JPT Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration 2011. Available from www.cochrane\u2010handbook.org."},{"key":"e_1_2_15_56_1","unstructured":"Dickersin 1990"},{"key":"e_1_2_15_57_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1990.03440100097014"},{"key":"e_1_2_15_58_1","doi-asserted-by":"crossref","unstructured":"Dodds 2009","DOI":"10.12968\/indn.2009.30.10.77066"},{"key":"e_1_2_15_59_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1445-2197.2009.05018.x"},{"key":"e_1_2_15_60_1","unstructured":"Donner 2001"},{"key":"e_1_2_15_61_1","doi-asserted-by":"publisher","DOI":"10.1177\/096228020101000502"},{"key":"e_1_2_15_62_1","unstructured":"Eisenstein 2008"},{"key":"e_1_2_15_63_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2008.01922.x"},{"key":"e_1_2_15_64_1","unstructured":"Engemann 2003"},{"key":"e_1_2_15_65_1","doi-asserted-by":"publisher","DOI":"10.1086\/367653"},{"key":"e_1_2_15_66_1","unstructured":"Eron 2003"},{"key":"e_1_2_15_67_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkg466"},{"key":"e_1_2_15_68_1","unstructured":"Falagas 2008"},{"key":"e_1_2_15_69_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(07)70312-2"},{"key":"e_1_2_15_70_1","unstructured":"FDA 1998"},{"key":"e_1_2_15_71_1","unstructured":"FDA. Uncomplicated and complicated skin and skin structure infections\u2010\u2010developing antimicrobial drugs for treatment. Guidance for Industry: Center for Drug Evaluation and Research (CDER).http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/ucm071185.pdf1998."},{"key":"e_1_2_15_72_1","unstructured":"Finch 2005"},{"key":"e_1_2_15_73_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dki004"},{"key":"e_1_2_15_74_1","unstructured":"Fritsche 2007"},{"key":"e_1_2_15_75_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2006.12.009"},{"key":"e_1_2_15_76_1","unstructured":"Fung 2001"},{"key":"e_1_2_15_77_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(01)80043-6"},{"key":"e_1_2_15_78_1","unstructured":"Fung 2003"},{"key":"e_1_2_15_79_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200363140-00003"},{"key":"e_1_2_15_80_1","unstructured":"Higgins 2003"},{"key":"e_1_2_15_81_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.327.7414.557"},{"key":"e_1_2_15_82_1","unstructured":"Higgins 2011a"},{"key":"e_1_2_15_83_1","unstructured":"HigginsJPT AltmanDG Sterne JAC(editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT Green S (editors).In: Higgins JPT Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration 2011. Available from www.cochrane\u2010handbook.org."},{"key":"e_1_2_15_84_1","unstructured":"Higgins 2011b"},{"key":"e_1_2_15_85_1","unstructured":"HigginsJPT GreenS (editors). Chapter 16: Special topics in statistics.In: Higgins JPT Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration 2011. Available from www.cochrane\u2010handbook.org."},{"key":"e_1_2_15_86_1","doi-asserted-by":"crossref","unstructured":"Jones 2009","DOI":"10.12968\/sece.2009.9.1590"},{"key":"e_1_2_15_87_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2009.10.001"},{"key":"e_1_2_15_88_1","unstructured":"Kollef 2004"},{"key":"e_1_2_15_89_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-003-2088-1"},{"key":"e_1_2_15_90_1","unstructured":"Lamagni 2008"},{"key":"e_1_2_15_91_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00422-08"},{"key":"e_1_2_15_92_1","unstructured":"Lefebvre 2011"},{"key":"e_1_2_15_93_1","unstructured":"LefebvreC ManheimerE GlanvilleJ on behalf of the Cochrane Information Retrieval Methods Group. Chapter 6: Searching for studies.In: Higgins JPT Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration 2011. Available from www.cochrane\u2010handbook.org."},{"key":"e_1_2_15_94_1","doi-asserted-by":"crossref","unstructured":"Levine 2006","DOI":"10.1215\/01636545-2006-95-262"},{"key":"e_1_2_15_95_1","doi-asserted-by":"publisher","DOI":"10.1086\/491709"},{"key":"e_1_2_15_96_1","unstructured":"Moellering 1999"},{"key":"e_1_2_15_97_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-130-2-199901190-00012"},{"key":"e_1_2_15_98_1","unstructured":"Moet 2006"},{"key":"e_1_2_15_99_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2006.05.009"},{"key":"e_1_2_15_100_1","unstructured":"Pallares 1993"},{"issue":"7","key":"e_1_2_15_101_1","first-page":"376","article-title":"Trends in antimicrobial utilization at a tertiary teaching hospital during a15\u2010year period (1978\u20131992)","volume":"14","author":"Pallares R","year":"1993","journal-title":"\u00a0Infection Control and Hospital Epidemiology"},{"key":"e_1_2_15_102_1","unstructured":"Schulz 1995"},{"key":"e_1_2_15_103_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1995.03520290060030"},{"key":"e_1_2_15_104_1","unstructured":"Shorr 2005"},{"key":"e_1_2_15_105_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dki355"},{"key":"e_1_2_15_106_1","unstructured":"SIGN 2008"},{"key":"e_1_2_15_107_1","unstructured":"Scottish Intercollegiate Guidelines Network (SIGN). Search filters.http:\/\/www.sign.ac.uk\/methodology\/filters.html#random(accessed 27 May 2008)."},{"key":"e_1_2_15_108_1","unstructured":"Sivagnanam 2003"},{"key":"e_1_2_15_109_1","doi-asserted-by":"publisher","DOI":"10.1186\/cc1871"},{"key":"e_1_2_15_110_1","unstructured":"Stevens 2005"},{"key":"e_1_2_15_111_1","doi-asserted-by":"publisher","DOI":"10.1086\/497143"},{"key":"e_1_2_15_112_1","unstructured":"Tsiodras 2001"},{"key":"e_1_2_15_113_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(01)05410-1"},{"key":"e_1_2_15_114_1","doi-asserted-by":"crossref","unstructured":"Wilson 2008","DOI":"10.1353\/hsp.2008.0069"},{"key":"e_1_2_15_115_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0804276105"},{"key":"e_1_2_15_116_1","unstructured":"Wunderink 2003"},{"key":"e_1_2_15_117_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0012-3692(15)33412-7"}],"container-title":["Evidence-Based Child Health: A Cochrane Review Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Febch.1961","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ebch.1961","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T02:01:47Z","timestamp":1700618507000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ebch.1961"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":116,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["10.1002\/ebch.1961"],"URL":"https:\/\/doi.org\/10.1002\/ebch.1961","archive":["Portico"],"relation":{},"ISSN":["1557-6272","1557-6272"],"issn-type":[{"value":"1557-6272","type":"print"},{"value":"1557-6272","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,3]]}}}